Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Newly Diagnosed High-grade Glioma
NCT07389278Phase 2Not yet recruiting
- Start
- Jun 2027
- Primary completion
- Jun 2032
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pegargiminase in glioma, diffuse midline glioma (DMG), diffuse hemispheric glioma (DHG), glioblastoma (GBM). Planned start Jun 2027; status: not yet recruiting.
02
Drugs
Pegargiminase
03
Conditions
gliomadiffuse midline glioma (DMG)diffuse hemispheric glioma (DHG)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07389278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389278.